New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
08:32 EDTFRX, ACTActavis, Forest Labs announce tentative election deadline of June 27
Actavis plc (ACT) and Forest Laboratories (FRX) announced that the tentative election deadline for Forest stockholders to elect the form of consideration they wish to receive in Actavisí planned acquisition of Forest is 5:00 p.m., Eastern time, on June 27. The Election Deadline may be extended, in which case Actavis and Forest will issue a press release announcing the new election deadline. Subject to regulatory approval and other customary closing conditions, the closing date of the acquisition is expected to be July 1. As previously announced, Forest stockholders can elect to receive, for each of their shares of Forest common stock, either cash, Actavis ordinary shares, or a combination of cash and Actavis ordinary shares. The cash and stock elections will be subject to proration and adjustment procedures, which are further described in the Joint Proxy Statement/Prospectus of Actavis and Forest, dated May 2. The documents necessary for Forest stockholders to make an election for their merger consideration were mailed beginning on May 30.
News For ACT;FRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
17:50 EDTACTActavis confirms District Court ruling that Atelvia patents are invalid
Subscribe for More Information
March 2, 2015
08:31 EDTACTActavis receives approval from Europcean Commission for Xydalba
Subscribe for More Information
February 27, 2015
08:04 EDTACTActavis and Medicines360 announce FDA approval of LILETTA
Subscribe for More Information
08:02 EDTACTFDA PDUFA Date for Actavis Nebivolol/Valsartan is February 27, 2015
February 25, 2015
17:26 EDTACTActavis' Avycaz for infections approved by FDA
Actavis' Avycaz has been approved by the FDA for the treatment of adult patients with complicated intra-abdominal infections and complicated urinary tract infections including pyelonephritis caused by designated susceptible bacteria, including certain Enterobacteriaceae and Pseudomonas aeruginosa. AVYCAZ received a priority review based on Phase II data from the company's clinical development program and supporting in vitro data, and as such should be reserved for use in patients who have limited or no alternative treatment options. AVYCAZ will be available in Q2.
08:19 EDTACTActavis price target raised to $350 from $315 at Bernstein
Subscribe for More Information
07:59 EDTACTActavis 13.2M share Secondary priced at $288.00
The deal size was lowered to $3.8B from $4.2B and but the convertible preferred was up-sized to $4.6B from $4.2B. JPMorgan, Mizuho, Wells Fargo and Morgan Stanley acted as joint book running managers for the offering.
February 24, 2015
16:27 EDTACTActavis confirms generic Uceris patent challenge
Actavis (ACT) confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Budesonide Extended-release Tablets, 9 mg. Actavis' ANDA product is a generic version of Salix Pharmaceuticals' (SLXP) Uceris, which is a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.
February 23, 2015
12:53 EDTACTAnalysts debate potential for competing Salix takeover bid
Subscribe for More Information
February 20, 2015
08:46 EDTACTActavis receives final approval for generic version of Subutex
Actavis announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Reckitt Benckiser's Subutex. Actavis intends to begin shipping its product shortly. Subutex is indicated for the treatment of opioid dependence. For the 12 months ending December 31, 2014, Subutex had total U.S. sales of approximately $108M, according to IMS Health data.
08:07 EDTACTActavis price target raised to $340 from $310 at Argus
Argus increased its price target on Actavis as the firm believes that the company is generating strong growth. Argus is upbeat on the company's acquisition of Allergan and keeps a Buy rating on the shares.
February 19, 2015
09:33 EDTACTActavis should be bought on weakness, says Sterne Agee
Subscribe for More Information
07:44 EDTACTActavis to sell 4.2B ordinary shares and $4.2B convertible preferred shares
Subscribe for More Information
07:40 EDTACTActavis price target raised to $352 from $300 at Canaccord
Subscribe for More Information
07:39 EDTACTActavis price target raised to $328 from $310 at Leerink
Subscribe for More Information
07:28 EDTACTActavis files automatic mixed securities shelf
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use